Beam Therapeutics
BEAM
24.77
-0.46
-1.82%
Beam Therapeutics
US · BEAM
#2614 by market cap
Listed 2020
24.77
-0.46
-1.82%
Live - 5344 symbols - heartbeat 564s ago
· 2026-10-08 06:33
Pre-market
24.25
-2.10%
After-hours
25.00
+0.91%
Overnight
24.72
-0.20%
- Market cap
- 2.56B
- P/E (TTM)i
- -35.90
- P/Bi
- 2.40
- EPSi
- -0.81
- Div yieldi
- 0.00%
- 52W posi
- 25%
Reader sentiment
Are you bullish or bearish on BEAM?
Anonymous reader poll. Unscientific, not investment advice.
About Beam Therapeutics
Beam Therapeutics, Inc. is a biotechnology company, which engages in the establishment of integrated platform for precision genetic medicines. Its pipeline includes BEAM-101, BEAM-302, Engineered Stem Cell Antibody Paired Evasion (ESCAPE), BEAM-301, and BEAM-201. The company was founded by David R. Liu, Feng Zhang, Alexis Komor, Nicole Gaudelli, and J. Keith Joung on January 25, 2017 and is headquartered in Cambridge, MA.
- Founded
- 2017
- CEO
- Mr. John Evans
- Employees
- 511
- Headquarters
- Cambridge, Massachusetts, United States of America
- Fiscal year end
- 12-31
- Website
- beamtx.com
Company profile
- Exchange
- US
- Symbol
- BEAM
- Market-cap rank
- #2614
- Listing date
- 2020-02-06
- Market cap
- 2.56B
- Float cap
- 2.27B
- Shares out
- 103.29M
- Float shares
- 91.69M
Sectors & themes
Quote time 2026-10-08 06:33:39 · For reference only, not investment advice and not tailored to your situation.